Novakand Pharma AB
3EE0
Company Profile
Business description
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.
Contact
Nanna Svarts vag 4
Solna171 65
SWET: +46 850126080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,351.90 | 4.90 | -0.05% |
| CAC 40 | 8,225.63 | 0.15 | -0.00% |
| DAX 40 | 24,239.89 | 32.10 | 0.13% |
| Dow JONES (US) | 47,207.12 | 472.51 | 1.01% |
| FTSE 100 | 9,645.62 | 67.05 | 0.70% |
| HKSE | 26,381.60 | 221.45 | 0.85% |
| NASDAQ | 23,204.87 | 263.07 | 1.15% |
| Nikkei 225 | 50,436.94 | 1,137.29 | 2.31% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,791.69 | 53.25 | 0.79% |
| S&P/ASX 200 | 9,055.60 | 2.20 | -0.02% |
| SSE Composite Index | 3,986.90 | 36.59 | 0.93% |